|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
CN105884893A
(zh)
|
2002-07-18 |
2016-08-24 |
莫鲁斯有限公司 |
抗体混合物的重组生产
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
US7608693B2
(en)
*
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
EP2245064B1
(en)
*
|
2007-12-21 |
2014-07-23 |
Medimmune Limited |
BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
PL3456190T3
(pl)
|
2008-06-27 |
2022-06-06 |
Merus N.V. |
Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
|
|
RU2553325C2
(ru)
*
|
2008-07-25 |
2015-06-10 |
Институт Фо Ресёч Ин Биомедицин |
Нейтрализующие антитела против вируса гриппа а и их использование
|
|
US8871207B2
(en)
|
2008-07-25 |
2014-10-28 |
Humabs, LLC |
Neutralizing anti-influenza A virus antibodies and uses thereof
|
|
AU2014216019B2
(en)
*
|
2008-10-29 |
2016-04-21 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to Human IL-4 receptor
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
EP2564695B1
(en)
*
|
2009-07-08 |
2015-04-15 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
ES2603559T5
(es)
|
2010-02-08 |
2021-02-22 |
Regeneron Pharma |
Cadena ligera común de ratón
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
CN104404050B
(zh)
*
|
2010-06-22 |
2018-06-08 |
瑞泽恩制药公司 |
杂交轻链小鼠
|
|
CA2807282A1
(en)
|
2010-08-02 |
2012-02-09 |
Regeneron Pharamaceuticals, Inc. |
Mice that make binding proteins comprising vl domains
|
|
AU2011312191B2
(en)
|
2010-10-06 |
2015-07-02 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
|
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
|
CN102830228B
(zh)
*
|
2011-06-15 |
2015-01-21 |
格诺思博生物科技(上海)有限公司 |
定量分析循环肿瘤细胞的试剂及试剂盒
|
|
AR087329A1
(es)
*
|
2011-06-17 |
2014-03-19 |
Regeneron Pharma |
Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
|
|
HRP20180858T1
(hr)
*
|
2011-07-11 |
2018-09-21 |
Glenmark Pharmaceuticals S.A. |
Protutijela koja se vežu na ox40 i njihove uporabe
|
|
MX352338B
(es)
|
2011-07-18 |
2017-11-17 |
Inst Res Biomedicine |
Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
|
|
FI3865581T3
(fi)
|
2011-08-05 |
2024-11-02 |
Regeneron Pharma |
Humanisoituja universaaleja kevytketjun hiiriä
|
|
ES2992345T3
(es)
|
2011-09-16 |
2024-12-11 |
Regeneron Pharma |
Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
|
|
CN103945689B
(zh)
*
|
2011-09-19 |
2016-10-19 |
科马布有限公司 |
免疫球蛋白基因多样性的操纵及多抗体治疗剂
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9706759B2
(en)
|
2011-12-20 |
2017-07-18 |
Regeneron Pharmaceuticals, Inc. |
Humanized light chain mice
|
|
RS57118B1
(sr)
|
2012-03-16 |
2018-06-29 |
Regeneron Pharma |
Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
CN104302170B
(zh)
|
2012-03-16 |
2016-09-28 |
瑞泽恩制药公司 |
生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
|
|
NZ730271A
(en)
|
2012-03-16 |
2022-09-30 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
PT2838917T
(pt)
|
2012-04-20 |
2019-09-12 |
Merus Nv |
Métodos e meios para a produção de moléculas similares a ig heterodiméricas
|
|
JP6306588B2
(ja)
|
2012-08-21 |
2018-04-04 |
サノフィ・バイオテクノロジー |
Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
TR201810255T4
(tr)
*
|
2013-02-20 |
2018-08-27 |
Regeneron Pharma |
Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
|
|
EP2958941B1
(en)
|
2013-02-20 |
2019-04-10 |
Innate Pharma |
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
|
|
MX2015013163A
(es)
|
2013-03-15 |
2016-04-04 |
Zyngenia Inc |
Complejos multiespecificos multivalente y monovalentes y sus usos.
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
EP3010539B1
(en)
|
2013-06-21 |
2019-07-24 |
Sanofi Biotechnology |
Methods for treating nasal polyposis by administering an il-4r antagonist
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
AU2014330922A1
(en)
|
2013-10-01 |
2016-03-03 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
RS60938B1
(sr)
|
2013-10-02 |
2020-11-30 |
Medimmune Llc |
Neutrališuća antitela na grip a i njihova upotreba
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
AU2015221388A1
(en)
*
|
2014-02-19 |
2016-08-04 |
Emergent Biosolutions Canada Inc. |
Methods of modulating an immune response
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
EP3110848B1
(en)
|
2014-02-28 |
2024-02-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating skin infection by administering an il-4r antagonist
|
|
SG11201607015VA
(en)
|
2014-03-21 |
2016-09-29 |
Regeneron Pharma |
V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
WO2016011035A2
(en)
|
2014-07-15 |
2016-01-21 |
Medlmmune, Llc |
Neutralizing anti-influenza b antibodies and uses thereof
|
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
JP6861630B2
(ja)
|
2014-11-14 |
2021-04-21 |
サノフィ・バイオテクノロジー |
Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
|
|
US10435476B2
(en)
|
2015-03-06 |
2019-10-08 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind JAG1
|
|
WO2016149678A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
JP6773679B2
(ja)
|
2015-03-30 |
2020-10-21 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
|
|
CN107683291B
(zh)
|
2015-04-02 |
2021-11-19 |
英特维特国际股份有限公司 |
针对犬白介素-4受体α的抗体
|
|
PT3303384T
(pt)
|
2015-06-01 |
2021-10-14 |
Medimmune Llc |
Moléculas de ligação neutralizantes anti-influenza e suas utilizações
|
|
CN106699888B
(zh)
*
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
|
TW202440903A
(zh)
*
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
CN106939047B
(zh)
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
|
IL304940A
(en)
|
2016-01-13 |
2023-10-01 |
Medimmune Llc |
A method for treating type A influenza
|
|
US10314904B2
(en)
|
2016-02-19 |
2019-06-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
|
|
CN113372446A
(zh)
|
2016-06-08 |
2021-09-10 |
苏州康乃德生物医药有限公司 |
用于结合白细胞介素4受体的抗体
|
|
CN118141914A
(zh)
|
2016-09-01 |
2024-06-07 |
瑞泽恩制药公司 |
用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
|
|
KR20190053250A
(ko)
|
2016-09-22 |
2019-05-17 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
|
|
US10485844B2
(en)
|
2016-09-22 |
2019-11-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
|
|
EP3525820A4
(en)
*
|
2016-10-17 |
2020-09-16 |
Vanderbilt University |
ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS AND THEIR USE METHODS
|
|
TWI857389B
(zh)
|
2016-12-01 |
2024-10-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
CN110234348B
(zh)
*
|
2016-12-16 |
2024-06-25 |
蓝鳍生物医药公司 |
抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
|
|
EP3957752B1
(en)
|
2017-04-13 |
2025-08-20 |
Regeneron Pharmaceuticals, Inc. |
Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
CN107216388B
(zh)
*
|
2017-08-07 |
2020-05-05 |
广州泰诺迪生物科技有限公司 |
一种治疗丙型肝炎病毒药物的制备方法和用途
|
|
EP4344706A3
(en)
|
2017-10-30 |
2024-05-22 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
CN108373505B
(zh)
*
|
2018-04-20 |
2019-08-20 |
北京智仁美博生物科技有限公司 |
抗il-4r抗体及其用途
|
|
MA52624A
(fr)
|
2018-05-13 |
2021-03-24 |
Regeneron Pharma |
Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
|
|
CN113101364B
(zh)
*
|
2018-05-29 |
2023-12-01 |
康诺亚生物医药科技（成都）有限公司 |
一种自免疫抑制剂的开发和应用
|
|
US11589562B2
(en)
*
|
2018-07-16 |
2023-02-28 |
Regeneran Pharmaceuticals, Inc. |
Mouse model of DITRA disease and uses thereof
|
|
MY205774A
(en)
|
2018-08-24 |
2024-11-12 |
Shanghai hengrui pharmaceutical co ltd |
Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
|
|
WO2020096381A1
(ko)
|
2018-11-09 |
2020-05-14 |
아주대학교 산학협력단 |
인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
|
|
CN110746507B
(zh)
|
2018-12-25 |
2020-06-26 |
江苏荃信生物医药有限公司 |
抗人白介素4受体α单克隆抗体及其应用
|
|
WO2020180727A1
(en)
|
2019-03-06 |
2020-09-10 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
|
|
WO2020191346A1
(en)
|
2019-03-21 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
CN113795262A
(zh)
*
|
2019-04-08 |
2021-12-14 |
东莞凡恩世生物医药有限公司 |
人源化抗dll3嵌合抗原受体及其用途
|
|
CN112010977B
(zh)
|
2019-05-29 |
2022-04-26 |
山东博安生物技术股份有限公司 |
抗白介素4受体(il-4r)的抗体及其应用
|
|
EP3999114A1
(en)
|
2019-07-16 |
2022-05-25 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
CN112279914A
(zh)
*
|
2019-07-25 |
2021-01-29 |
苏州丁孚靶点生物技术有限公司 |
Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
|
|
SG11202113310UA
(en)
|
2019-08-05 |
2021-12-30 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
EP4010001A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
AU2020399975A1
(en)
|
2019-12-09 |
2022-07-28 |
Sanofi Biotechnology |
Methods for treating digitally-identified IL-4/IL-13 related disorders
|
|
US20230075244A1
(en)
*
|
2020-02-20 |
2023-03-09 |
The Feinstein Institutes For Medical Research |
Agonist antibodies against endoglin and uses thereof
|
|
BR112022016345A2
(pt)
|
2020-02-21 |
2022-12-20 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composição farmacêutica contendo anticorpo anti-il-4r e uso da mesma
|
|
WO2021170020A1
(en)
*
|
2020-02-27 |
2021-09-02 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antibodies binding il4r and uses thereof
|
|
WO2021195530A1
(en)
|
2020-03-27 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
JP2023521174A
(ja)
*
|
2020-04-10 |
2023-05-23 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体
|
|
CN113527485B
(zh)
|
2020-04-17 |
2024-11-15 |
湖南麦济生物技术股份有限公司 |
抗人白细胞介素-4受体α抗体及其制备方法和应用
|
|
CN113549151A
(zh)
*
|
2020-04-24 |
2021-10-26 |
苏州康乃德生物医药有限公司 |
与人IL-4Rα中特定表位结合的抗体及其应用
|
|
US20250154267A2
(en)
|
2020-05-22 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
|
|
CN116348605A
(zh)
|
2020-07-17 |
2023-06-27 |
Gi 医诺微新 |
包含IgE Fc受体α亚基胞外结构域和抗IL-4R抗体的融合蛋白及其应用
|
|
KR102697769B1
(ko)
|
2020-09-14 |
2024-08-23 |
아주대학교산학협력단 |
인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
|
|
US20220169739A1
(en)
|
2020-10-05 |
2022-06-02 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
|
TW202231663A
(zh)
|
2020-12-22 |
2022-08-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｉｌ－４ｒ抗體或其抗原結合片段的複合物及醫藥用途
|
|
US20220220211A1
(en)
|
2021-01-08 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|
|
MX2023008142A
(es)
*
|
2021-01-08 |
2023-09-08 |
Bristol Myers Squibb Co |
Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y usos de los mismos.
|
|
KR20240037321A
(ko)
|
2021-07-26 |
2024-03-21 |
사노피 바이오테크놀로지 |
Il-4r 길항제의 투여에 의한 만성 자발성 심마진의 치료 방법
|
|
TWI876192B
(zh)
*
|
2021-08-05 |
2025-03-11 |
美商美國禮來大藥廠 |
人類介白素-4受體α抗體
|
|
CA3227014A1
(en)
|
2021-08-23 |
2023-03-02 |
Ashish Bansal |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
TW202313692A
(zh)
*
|
2021-08-26 |
2023-04-01 |
大陸商正大天晴藥業集團股份有限公司 |
抗ｉｌ４ｒ抗體的藥物組成物及其用途
|
|
AU2022369296A1
(en)
|
2021-10-20 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
|
WO2023130010A1
(en)
|
2021-12-30 |
2023-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for attenuating atopic march by administering an il-4/il-13 antagonist
|
|
CN118678972A
(zh)
|
2022-01-29 |
2024-09-20 |
上海盛迪医药有限公司 |
糖皮质激素的药物偶联物
|
|
WO2023167855A1
(en)
|
2022-03-02 |
2023-09-07 |
Regeneron Pharmaceuticals, Inc. |
Manufacturing process for high titer antibody
|
|
CA3250514A1
(en)
|
2022-05-02 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIES
|
|
US20240199688A1
(en)
|
2022-05-02 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity
|
|
KR20250037491A
(ko)
|
2022-07-08 |
2025-03-17 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제 투여에 의한 소아 호산구성 식도염을 치료하는 방법
|
|
CN120091829A
(zh)
|
2022-08-29 |
2025-06-03 |
赛诺菲生物技术公司 |
通过施用il-4r拮抗剂治疗慢性诱导性寒冷性荨麻疹的方法
|
|
TW202432598A
(zh)
|
2022-11-01 |
2024-08-16 |
美商再生元醫藥公司 |
藉由投予il-4r拮抗劑治療手足皮膚炎的方法
|
|
WO2024112935A1
(en)
|
2022-11-23 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for improving bone growth by administering an il-4r antagonist
|
|
KR20250160361A
(ko)
|
2023-03-22 |
2025-11-12 |
사노피 바이오테크놀로지 |
Il-4r 길항제를 투여하여 만성 폐쇄성 폐 질환(copd)을 치료하는 방법
|
|
CN121001741A
(zh)
|
2023-03-27 |
2025-11-21 |
瑞泽恩制药公司 |
用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法
|
|
WO2025075970A1
(en)
|
2023-10-02 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Drug delivery device safety system
|
|
TW202535934A
(zh)
|
2023-11-02 |
2025-09-16 |
美商再生元醫藥公司 |
利用應力來降低脂酶活性的方法
|
|
US20250230251A1
(en)
|
2023-12-20 |
2025-07-17 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rb) and related methods
|
|
WO2025221640A1
(en)
|
2024-04-15 |
2025-10-23 |
Sanofi Biotechnology |
Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
|